Multi-omics analysis reveals the prognostic and tumor micro-environmental value of lumican in multiple cancer typesZehuai Guo, Yang Cao, Zhe Sun et al.|Frontiers in Molecular Biosciences|2023Cited by 7
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot StudyWenmin Chen, Lizhu Lin, Jietao Lin et al.|Integrative Cancer Therapies|2023Cited by 6